Medication info
Gabli Tablet (Vildagliptin)

Gabli Tablet (Vildagliptin)

Prescription medicationTablet
Ingredient · strength
Vildagliptin›50mg / 1 tablet
Manufacturer / importer
Shinpoong Pharmaceutical Co., Ltd.
Appearance
Round tablet with white to light yellow color
Packaging
PTP - 30 tablets/box[(10 tablets/PTP×3)]
Approval status
Active

MFDS item code 202200347 · Approved 2022.01.19 · Insurance code 648507970

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who uses it
Adults
Adult dosage
- For monotherapy, or when administered with metformin in patients who have not previously received pharmacological treatment for diabetes, this drug is administered at 50mg once daily in the morning or at 100mg per day, divided into 50mg twice daily in the morning and evening. - When glycemic control is inadequate with metformin or thiazolidinedione monotherapy, the recommended dose of this drug when administered with metformin or a thiazolidinedione is 100mg per day, divided into 50mg twice daily in the morning and evening. - When glycemic control is inadequate with sulfonylurea monotherapy, the recommended dose of this drug when administered with a sulfonylurea is 50mg once daily in the morning. In this patient group, vildagliptin 100mg once daily was not more effective than 50mg once daily. - When glycemic control is inadequate with combination therapy of a sulfonylurea and metformin, the recommended dose of this drug as add-on therapy (triple therapy) is 100mg per day, divided into 50mg twice daily in the morning and evening. - When glycemic control is inadequate with insulin therapy (insulin alone or in combination with metformin), the recommended dose of this drug as add-on therapy is 100mg per day, divided into 50mg twice daily in the morning and evening. - This drug may be taken with or without food. Doses exceeding 100mg per day are not recommended. - When this drug is used in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia. - If you forget to take this drug, take it as soon as you remember and take the next dose at the usual time. If you remember close to the time of your next dose, skip the missed dose. Do not take a double dose at one time to make up for a missed dose. Patients with hepatic impairment This drug is not recommended for patients with hepatic impairment whose ALT or AST levels exceed 2.5 times the upper limit of normal before treatment. Patients with renal impairment - Patients with mild renal impairment (creatinine clearance ≥50mL/min): No dose adjustment is required. - Patients with moderate or severe renal impairment, or end-stage renal disease (ESRD): A dose of 50mg once daily is recommended. (See section 3, General Precautions, subsection 2, in Precautions for Use.)

Ingredients

Manufacturer
Shinpoong Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Blood sugar control disorder in patients with type 2 diabetes
View approved original text

This medication is an adjunct to help patients with type 2 diabetes achieve better blood sugar control alongside dietary and exercise therapy. It can be prescribed alone or in combination with other blood sugar-lowering medications. This helps maintain stable blood sugar levels and contributes to the prevention of complications. It should be used appropriately according to the patient's condition to improve blood sugar control.

Dosage and Administration

Adult dosage

- For monotherapy, or when administered with metformin in patients who have not previously received pharmacological treatment for diabetes, this drug is administered at 50mg once daily in the morning or at 100mg per day, divided into 50mg twice daily in the morning and evening. - When glycemic control is inadequate with metformin or thiazolidinedione monotherapy, the recommended dose of this drug when administered with metformin or a thiazolidinedione is 100mg per day, divided into 50mg twice daily in the morning and evening. - When glycemic control is inadequate with sulfonylurea monotherapy, the recommended dose of this drug when administered with a sulfonylurea is 50mg once daily in the morning. In this patient group, vildagliptin 100mg once daily was not more effective than 50mg once daily. - When glycemic control is inadequate with combination therapy of a sulfonylurea and metformin, the recommended dose of this drug as add-on therapy (triple therapy) is 100mg per day, divided into 50mg twice daily in the morning and evening. - When glycemic control is inadequate with insulin therapy (insulin alone or in combination with metformin), the recommended dose of this drug as add-on therapy is 100mg per day, divided into 50mg twice daily in the morning and evening. - This drug may be taken with or without food. Doses exceeding 100mg per day are not recommended. - When this drug is used in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia. - If you forget to take this drug, take it as soon as you remember and take the next dose at the usual time. If you remember close to the time of your next dose, skip the missed dose. Do not take a double dose at one time to make up for a missed dose. Patients with hepatic impairment This drug is not recommended for patients with hepatic impairment whose ALT or AST levels exceed 2.5 times the upper limit of normal before treatment. Patients with renal impairment - Patients with mild renal impairment (creatinine clearance ≥50mL/min): No dose adjustment is required. - Patients with moderate or severe renal impairment, or end-stage renal disease (ESRD): A dose of 50mg once daily is recommended. (See section 3, General Precautions, subsection 2, in Precautions for Use.)

Precautions

This medication should not be used in patients with allergic reactions to the active ingredient or other components. It should not be administered to patients with type 1 diabetes or diabetic ketoacidosis. This medication contains lactose, so patients with genetic issues such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption should not take it. During the use of this medication, rare liver function abnormalities may occur, so regular liver function tests should be conducted before and during treatment. If liver enzyme levels remain elevated above three times the normal upper limit, the medication should be discontinued, and immediate consultation with a healthcare provider is necessary if symptoms suggesting liver dysfunction appear. This medication carries a risk of acute pancreatitis, so patients should inform their doctor immediately if they experience abdominal pain or indigestion during treatment. Care should be taken when used with medications that can cause hypoglycemia, such as sulfonylureas, as the risk of hypoglycemia may increase. If symptoms like dizziness occur, it is safer to avoid driving or operating machinery. This medication is not recommended for pregnant or breastfeeding women, and should especially not be used during pregnancy. No dosage adjustment is necessary for the elderly, but its use is not recommended for children or adolescents under 18 years of age. In case of overdose, as there is no specific antidote, it is important to receive appropriate treatment based on symptoms. This medication should be stored out of reach of children, and transferring it to another container should be avoided.

Side effects

Hepatitis, abnormal liver function, elevated transaminase levels, angioedema, tremors, headache, dizziness, fatigue, nausea, hypoglycemia, pharyngitis, asthenia, constipation, weight gain, peripheral edema, gastroesophageal reflux, diarrhea, abdominal distension, chills, decreased blood glucose, hyperhidrosis, pancreatitis, urticaria, blisters, exfoliative skin lesions, severe joint pain associated with disability, cutaneous vasculitis, cholecystitis, upper respiratory infection, chest discomfort, dyspnea, acute myocardial infarction, cough, dyspepsia, drowsiness, vertigo, pruritus, dry mouth, vomiting, insomnia, renal impairment, lip blisters, hunger, sensory loss, spinal canal stenosis, abdominal pain, gastroenteritis, gastric inflammation, gastric ulcer, belching, appendicitis, fatty liver, hyperkalemia, hypertriglyceridemia, heart failure, cardiac hypertrophy, angina pectoris, cardiac arrest, renal cysts, lung carcinoma, leg pain, increased C-reactive protein, myalgia, paresthesia, fever, edema, elevated creatine phosphokinase, elevated AST, increased C-reactive protein, elevated myoglobin levels, hand and foot edema, upper respiratory infection, vesicular pemphigoid, dizziness, asthenia, joint pain, constipation, hypoglycemia, peripheral edema, nausea, gastroesophageal reflux, diarrhea, abdominal distension, chills, decreased blood glucose, hyperhidrosis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it should be stored in a tightly sealed container. Additionally, keeping it in a cool place at or below 30 degrees Celsius is essential for maintaining its efficacy.

Appearance and packaging

Appearance

Round tablet with white to light yellow color

Package unit

PTP - 30 tablets/box[(10 tablets/PTP×3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.